Anticoagulant drugs known as low-molecular-weight heparin (LMWH) are a kind of anticoagulant. They're used to prevent blood clots and treat venous thromboembolism (including deep vein thrombosis and pulmonary embolism) as well as myocardial infarction.
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa account for the majority of the worldwide low molecular weight heparin market. Because of the growth in the senior population, which has an influence on the prevalence of venous thrombosis, Europe and North America have a considerable market share. According to the European Commission (Eurostat), Europe's geriatric population is expected to reach 525 million by 2035. Because of the rising birth rate, the Asia Pacific and Middle East & Africa markets are expected to rise throughout the projection period. Due to its inability to penetrate the placenta, the National Institute for Health and Care Excellence (NICE) and the Royal College of Obstetricians and Gynaecologists (RCOG) suggest low molecular weight heparin as the best heparin to use during pregnancy.
Pharmaceutical firms manufactured branded low molecular weight heparin as biosimilars or called generic equivalents. In particular, enoxaparin is available across North and Latin America, as well as Asia. Regulatory organisations in Australia and Europe have created unique standards for biosimilar LMWH authorisation. Africa has thus far been left out of this process.
Read more @ https://cmiaspireblog.blogspot.com/2021/12/low-molecular-weight-heparin-market.html
